GTP-State-Selective Cyclic Peptide Ligands of K-Ras(G12D) Block Its Interaction with Raf
Open accessThe DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
translation-mRNA display selection platform. These cyclic peptides show preferential binding to the GTP-bound state of K-Ras(G12D) over the GDP-bound state and block Ras-Raf interaction. A co-crystal structure of peptide KD2 with K-Ras(G12D)·GppNHp reveals that this peptide binds in the Switch II groove region with concomitant opening of the Switch II loop and a 40° rotation of the α2 helix, and that a threonine residue (Thr10) on KD2 has direct access to the mutant aspartate (Asp12) on K-Ras. Replacing this threonine with non-natural amino acids afforded peptides with improved potency at inhibiting the interaction between Raf1-RBD and K-Ras(G12D) but not wildtype K-Ras. The union of G12D over wildtype selectivity and GTP state/GDP state selectivity is particularly desirable, considering that oncogenic K-Ras(G12D) exists predominantly in the GTP state in cancer cells, and wildtype K-Ras signaling is important for the maintenance of healthy cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Notably, these compounds have no discernable effect on wild-type KRAS, exemplifying the distinct features of the GTP-bound state of KRAS mutants174.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [174]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These include DARPins [71], cyclic peptides [72], KRAS–RAF protein–protein interaction inhibitors [73], and KRAS–GAP molecular glue-based approaches [74].”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [72]
In the citing paper
“In 2020, Zhang et al.174 identified three cyclic peptide ligands that are unique in that they bind preferentially within the switch 2 groove of KRASG12D-GTP and inhibit its interaction with RAF proteins.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [174]
In the citing paper
“cyclic peptide scaffolds have been reported to bind to KRASG12D and inhibit its interaction with CRAF at high nanomolar concentrations, albeit currently lacking cellular activity (32).”
From Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants (2022) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Self-citationThe Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277
A Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063
Physiological concentrations of purines and pyrimidines
Traut, T. W. (1994) · Molecular and Cellular Biochemistry · doi:10.1007/bf00928361 · Cited by 1,867
Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor
Janes, M. R., Zhang, J., Li, L.-S., Hansen, R., Peters, U., Guo, X., Chen, Y., Babbar, A., Firdaus, S. J., Darjania, L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.006 · Cited by 1,172
Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations
Hunter, J. C., Manandhar, A., Carrasco, M. A., Gurbani, D., Gondi, S., & Westover, K. D. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0203 · Cited by 786 · cited 1×
“2,3 As a result, K-Ras(G12D) is enriched in its GTP-bound, signaling-competent state, given the near 10-fold higher concentration of GTP than GDP inside the cell.”
Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state
Patricelli, M. P., Janes, M. R., Li, L.-S., Hansen, R., Peters, U., Kessler, L. V., Chen, Y., Kucharski, J. M., Feng, J., Ely, T., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1105 · Cited by 759
Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design
Ostrem, J. M. L., & Shokat, K. M. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.139 · Cited by 641 · cited 1×
“2,3 As a result, K-Ras(G12D) is enriched in its GTP-bound, signaling-competent state, given the near 10-fold higher concentration of GTP than GDP inside the cell.”
Self-citationMaurer, T., Garrenton, L. S., Oh, A., Pitts, K., Anderson, D. J., Skelton, N. J., Fauber, B. P., Pan, B., Malek, S., Stokoe, D., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1116510109 · Cited by 618
Understanding Cell Penetration of Cyclic Peptides
Dougherty, P. G., Sahni, A., & Pei, D. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00008 · Cited by 570
Discovery of Small Molecules that Bind to K‐Ras and Inhibit Sos‐Mediated Activation
Sun, Q., Burke, J. P., Phan, J., Burns, M. C., Olejniczak, E. T., Waterson, A. G., Lee, T., Rossanese, O. W., & Fesik, S. W. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201201358 · Cited by 490
Drugging an undruggable pocket on KRAS
Kessler, D., Gmachl, M., Mantoulidis, A., Martin, L. J., Zoephel, A., Mayer, M., Gollner, A., Covini, D., Fischer, S., Gerstberger, T., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1904529116 · Cited by 449
Dynamic properties of the Ras switch I region and its importance for binding to effectors
Spoerner, M., Herrmann, C., Vetter, I. R., Kalbitzer, H. R., & Wittinghofer, A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081441398 · Cited by 325
Therapeutic Targeting of Oncogenic K‐Ras by a Covalent Catalytic Site Inhibitor
Lim, S. M., Westover, K. D., Ficarro, S. B., Harrison, R. A., Choi, H. G., Pacold, M. E., Carrasco, M., Hunter, J., Kim, N. D., Xie, T., et al. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307387 · Cited by 300
An orthosteric inhibitor of the Ras-Sos interaction
Patgiri, A., Yadav, K. K., Arora, P. S., & Bar-Sagi, D. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.612 · Cited by 295
Shima, F., Yoshikawa, Y., Ye, M., Araki, M., Matsumoto, S., Liao, J., Hu, L., Sugimoto, T., Ijiri, Y., Takeda, A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1217730110 · Cited by 293
Quantifying the chameleonic properties of macrocycles and other high-molecular-weight drugs
Whitty, A., Zhong, M., Viarengo, L., Beglov, D., Hall, D. R., & Vajda, S. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.02.005 · Cited by 285
Inhibition of RAS function through targeting an allosteric regulatory site
Spencer-Smith, R., Koide, A., Zhou, Y., Eguchi, R. R., Sha, F., Gajwani, P., Santana, D., Gupta, A., Jacobs, M., Herrero-Garcia, E., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2231 · Cited by 283
Multivalent Small-Molecule Pan-RAS Inhibitors
Welsch, M. E., Kaplan, A., Chambers, J. M., Stokes, M. E., Bos, P. H., Zask, A., Zhang, Y., Sanchez-Martin, M., Badgley, M. A., Huang, C. S., et al. (2017) · Cell · doi:10.1016/j.cell.2017.02.006 · Cited by 274
Hunter, J. C., Gurbani, D., Ficarro, S. B., Carrasco, M. A., Lim, S. M., Choi, H. G., Xie, T., Marto, J. A., Chen, Z., Gray, N. S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1404639111 · Cited by 242
Geyer, M., Schweins, T., Herrmann, C., Prisner, T., Wittinghofer, A., & Kalbitzer, H. R. (1996) · Biochemistry · doi:10.1021/bi952858k · Cited by 230
A RaPID way to discover nonstandard macrocyclic peptide modulators of drug targets
Passioura, T., & Suga, H. (2017) · Chemical Communications · doi:10.1039/c6cc06951g · Cited by 193
Self-citationAhlbach, C. L., Lexa, K. W., Bockus, A. T., Chen, V., Crews, P., Jacobson, M. P., & Lokey, R. S. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.78 · Cited by 178
Bicyclic Peptides as Next‐Generation Therapeutics
Rhodes, C. A., & Pei, D. (2017) · Chemistry – A European Journal · doi:10.1002/chem.201702117 · Cited by 177
Cell Penetration Profiling Using the Chloroalkane Penetration Assay
Peraro, L., Deprey, K. L., Moser, M. K., Zou, Z., Ball, H. L., Levine, B., & Kritzer, J. A. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b06144 · Cited by 175
Fakih, M., O'Neil, B., Price, T. J., Falchook, G. S., Desai, J., Kuo, J., Govindan, R., Rasmussen, E., Morrow, P. K. H., Ngang, J., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.3003 · Cited by 172
The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors
Hansen, R., Peters, U., Babbar, A., Chen, Y., Feng, J., Janes, M. R., Li, L.-S., Ren, P., Liu, Y., & Zarrinkar, P. P. (2018) · Nature Structural & Molecular Biology · doi:10.1038/s41594-018-0061-5 · Cited by 153
Bockus, A. T., Lexa, K. W., Pye, C. R., Kalgutkar, A. S. S., Gardner, J. W., Hund, K. C. R., Hewitt, W. M., Schwochert, J. A., Glassey, E., Price, D. A., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00128 · Cited by 147
Trinh, T. B., Upadhyaya, P., Qian, Z., & Pei, D. (2015) · ACS Combinatorial Science · doi:10.1021/acscombsci.5b00164 · Cited by 129
Ras Binder Induces a Modified Switch-II Pocket in GTP and GDP States
Gentile, D. R., Rathinaswamy, M. K., Jenkins, M. L., Moss, S. M., Siempelkamp, B. D., Renslo, A. R., Burke, J. E., & Shokat, K. M. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.08.025 · Cited by 128 · cited 3×
“33 Structure-guided chemical diversi fi cation allowed rapid optimization of one initial hit into a compound with sub-micromolar potency at inhibiting Ras-Raf interaction.”
InfluentialSelf-citationTaveras, A. G., Remiszewski, S., Doll, R. J., Cesarz, D., Huang, E. C., Kirschmeier, P. T., Pramanik, B. N., Snow, M. E., Wang, Y.-S., del Rosario, J., et al. (1997) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(96)00202-7 · Cited by 123
Ribosomal Synthesis of Bicyclic Peptides via Two Orthogonal Inter-Side-Chain Reactions
Sako, Y., Morimoto, J., Murakami, H., & Suga, H. (2008) · Journal of the American Chemical Society · doi:10.1021/ja800953c · Cited by 122
Self-citationK-Ras(G12D)-selective inhibitory peptides generated by random peptide T7 phage display technology
Sakamoto, K., Kamada, Y., Sameshima, T., Yaguchi, M., Niida, A., Sasaki, S., Miwa, M., Ohkubo, S., Sakamoto, J.-I., Kamaura, M., et al. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.01.147 · Cited by 118
Structural and functional characterization of a DARPin which inhibits Ras nucleotide exchange
Guillard, S., Kolasinska-Zwierz, P., Debreczeni, J., Breed, J., Zhang, J., Bery, N., Marwood, R., Tart, J., Overman, R., Stocki, P., et al. (2017) · Nature Communications · doi:10.1038/ncomms16111 · Cited by 102
Martín‐Gago, P., Fansa, E. K., Klein, C. H., Murarka, S., Janning, P., Schürmann, M., Metz, M., Ismail, S., Schultz‐Fademrecht, C., Baumann, M., et al. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201610957 · Cited by 99
Peptide to Peptoid Substitutions Increase Cell Permeability in Cyclic Hexapeptides
Schwochert, J. A., Turner, R. A., Thang, M., Berkeley, R. F., Ponkey, A. R., Rodriguez, K. M., Leung, S. S. F., Khunte, B., Goetz, G. H., Limberakis, C., et al. (2015) · Organic Letters · doi:10.1021/acs.orglett.5b01162 · Cited by 87
Sogabe, S., Kamada, Y., Miwa, M., Niida, A., Sameshima, T., Kamaura, M., Yonemori, K., Sasaki, S., Sakamoto, J.-I., & Sakamoto, K. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00128 · Cited by 83
Progestin and breast cancer risk: a systematic review
Samson, M. E., Porter, N. R., Orekoya, O., Hébert, J. R., Adams, S. A., Bennett, C. L., & Steck, S. E. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3663-1 · Cited by 83
Inhibition of Ras–effector interactions by cyclic peptides
Wu, X., Upadhyaya, P., Villalona-Calero, M. A., Briesewitz, R., & Pei, D. (2013) · MedChemComm · doi:10.1039/c2md20329d · Cited by 68
The small molecule BI-2852 induces a nonfunctional dimer of KRAS
Tran, T. H., Alexander, P., Dharmaiah, S., Agamasu, C., Nissley, D. V., McCormick, F., Esposito, D., Simanshu, D. K., Stephen, A. G., & Balius, T. E. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1918164117 · Cited by 65
K-RasG12D Has a Potential Allosteric Small Molecule Binding Site
Feng, H., Zhang, Y., Bos, P. H., Chambers, J. M., Dupont, M. M., & Stockwell, B. R. (2019) · Biochemistry · doi:10.1021/acs.biochem.8b01300 · Cited by 57
Sticking it to KRAS: Covalent Inhibitors Enter the Clinic
McCormick, F. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.12.009 · Cited by 56
Niida, A., Sasaki, S., Yonemori, K., Sameshima, T., Yaguchi, M., Asami, T., Sakamoto, K., & Kamaura, M. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.04.063 · Cited by 42
Exceptionally high-affinity Ras binders that remodel its effector domain
McGee, J. H., Shim, S. Y., Lee, S.-J., Swanson, P. K., Jiang, S. Y., Durney, M. A., & Verdine, G. L. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.816348 · Cited by 40
Papadopoulos, K. P., Ou, S.-H. I., Johnson, M. L., Christensen, J., Velastegui, K., Potvin, D., Faltaos, D., & Chao, R. C. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.tps3161 · Cited by 37
Bridged bicyclic peptides: Structure and function
Thombare, V. J., & Hutton, C. A. (2018) · Peptide Science · doi:10.1002/pep2.24057 · Cited by 25
Pan‐Selective Aptamers for the Family of Small GTPases
Hons, M., Niebel, B., Karnowski, N., Weiche, B., & Famulok, M. (2012) · ChemBioChem · doi:10.1002/cbic.201200164 · Cited by 6
Cited by
KRAS Mutation: From Undruggable to Druggable in Cancer
Huang, L., Guo, Z., Wang, F., & Fu, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00780-4 · Cited by 1,127
The current state of the art and future trends in RAS-targeted cancer therapies
Punekar, S. R., Velcheti, V., Neel, B. G., & Wong, K.-K. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00671-9 · Cited by 549
Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants
Hofmann, M. H., Gerlach, D., Misale, S., Petronczki, M., & Kraut, N. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1331 · Cited by 336
“Indeed, recently cyclic peptide scaffolds have been reported to bind to KRASG12D and inhibit its interaction with CRAF at high nanomolar concentrations, albeit currently lacking cellular activity (32).”
BackgroundBond, M. J., & Crews, C. M. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00011j · Cited by 221
KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge
Mao, Z., Xiao, H., Shen, P., Yang, Y., Xue, J., Yang, Y., Shang, Y., Zhang, L., Li, X., Zhang, Y., et al. (2022) · Cell Discovery · doi:10.1038/s41421-021-00368-w · Cited by 158
Metadata
- Authors
- Zhang, Z., Gao, R., Hu, Q., Peacock, H., Peacock, D. M., Dai, S., Shokat, K. M., & Suga, H.
- Affiliations
- Howard Hughes Medical Institute (US)
- The University of Tokyo (JP)
- Corresponding author
- Shokat, Kevan M.
- Suga, Hiroaki
- ORCID
- Venue
- ACS Central Science
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-09-23
- Volume
- 6
- Issue
- 10
- Pages
- 1753-1761
- ISSN
- 2374-7943 (ISSN-L)
- 2374-7951
- PMC
- PMC7596874
- OpenAlex
- W3089129315
- Cited by
- 124
- References
- 47
- Citations by year
- 2026: 16 · 2025: 15 · 2024: 25 · 2023: 20 · 2022: 22 · 2021: 25 · 2020: 1
- FWCI
- 5.81
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- Locations
- ACS Central Science (publishedVersion, other-oa)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Cancer Institute (1R01CA244550)
- Damon Runyon Cancer Research Foundation (DRG-2229-15, DRG-2281-17)
- Samuel Waxman Cancer Research Foundation
- Mark Foundation For Cancer Research (SU2C)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- KRAS G12D, Raf, Ras-Raf interaction, cyclic peptide ligands, unnatural amino acids, oncogenic Ras
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.